Brief: Enlivex Receives Notice Of Allowance For U.S. Patent Application Covering Methods Of Treating Sepsis With Allocetra™
03/08/2022 13:19
Aug 3 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX RECEIVES NOTICE OF ALLOWANCE FOR U.S. PATENT
APPLICATION
COVERING METHODS OF TREATING SEPSIS WITH ALLOCETRA™
* ENLIVEX THERAPEUTICS LTD- EXPECTS THAT THIS NEW PATENT
WILL BE
ISSUED IN UNITED STATES IN Q4 OF 2022
* ENLIVEX THERAPEUTICS LTD- SEPSIS PROGRAM INCLUDES AN
ONGOING
PLACEBO-CONTROLLED, RANDOMIZED, DOSE-FINDING, MULTI-CENTER PHASE
II TRIAL
* ENLIVEX THERAPEUTICS LTD- INTERIM RESULTS FROM
MULTI-CENTER
PHASE II TRIAL ARE EXPECTED IN Q1 OF 2023
* ENLIVEX THERAPEUTICS LTD- TOP-LINE DATA FROM MULTI-CENTER
PHASE
II TRIAL ARE EXPECTED IN Q3 OF 2023
Source text for Eikon: ID:nGNX7D7nCl
Further company coverage: ENLV.TA
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment